Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

SAB Biotherapeutics (SABSW) Receivables - Net (2020 - 2023)

SAB Biotherapeutics' Receivables - Net history spans 4 years, with the latest figure at $364117.0 for Q2 2023.

  • For Q2 2023, Receivables - Net fell 96.21% year-over-year to $364117.0; the TTM value through Jun 2023 reached $364117.0, down 96.21%, while the annual FY2022 figure was $5.6 million, 30.64% down from the prior year.
  • Receivables - Net reached $364117.0 in Q2 2023 per SABSW's latest filing, down from $763123.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $20.6 million in Q4 2020 to a low of $364117.0 in Q2 2023.
  • Average Receivables - Net over 4 years is $8.7 million, with a median of $8.8 million recorded in 2021.
  • Peak YoY movement for Receivables - Net: tumbled 30.64% in 2022, then tumbled 96.21% in 2023.
  • A 4-year view of Receivables - Net shows it stood at $20.6 million in 2020, then plummeted by 61.06% to $8.0 million in 2021, then crashed by 30.64% to $5.6 million in 2022, then crashed by 93.45% to $364117.0 in 2023.
  • Per Business Quant, the three most recent readings for SABSW's Receivables - Net are $364117.0 (Q2 2023), $763123.0 (Q1 2023), and $5.6 million (Q4 2022).